<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853251</url>
  </required_header>
  <id_info>
    <org_study_id>ML43000</org_study_id>
    <nct_id>NCT04853251</nct_id>
  </id_info>
  <brief_title>A Study Of The Efficacy And Safety Of The Port Delivery System With Ranibizumab In Patients With Neovascular Age-Related Macular Degeneration Previously Treated With Intravitreal Agents Other Than Ranibizumab</brief_title>
  <acronym>Belvedere</acronym>
  <official_title>A Phase IIIb/IV, Multicenter, Open-Label, Single-Arm Study Of The Efficacy And Safety Of The Port Delivery System With Ranibizumab In Patients With Neovascular Age-Related Macular Degeneration Previously Treated With Intravitreal Agents Other Than Ranibizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study ML43000 is a Phase IIIb/IV multicenter, open-label (visual assessor-masked) study&#xD;
      designed to assess the efficacy and safety of PDS 100 mg/mL Q24W in patients with nAMD who&#xD;
      have been previously treated with anti-VEGF agents other than ranibizumab. Approximately 200&#xD;
      patients will be enrolled at approximately 40 sites.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">August 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in Best Corrected Visual Acuity (BCVA) letter score at Week 40, as assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart at a starting distance of 4 meters</measure>
    <time_frame>Baseline up to Week 40</time_frame>
    <description>PDS 100 mg/mL Q24W in nAMD particpants previously treated with intravitreal anti-VEGF agents other than ranibizumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in BCVA letter score at Week 40, as assessed using the ETDRS visual acuity chart at a starting distance of 4 meters</measure>
    <time_frame>Baseline up to Week 40</time_frame>
    <description>PDS 100 mg/mL Q24W in participants with nAMD by subgroup as defined by the last two consecutive anti-VEGF agent administered to the study eye prior to Day 1, aflibercept or bevacizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with BCVA score of 69 letters (approximate 20/40 Snellen equivalent) or better at each scheduled visit over time to Week 52</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who lose &lt; 15, &lt; 10, &lt; 5, or gain ≥ 0, &gt; 0, ≥ 5, ≥ 10, or ≥15 letters in BCVA score from baseline at each scheduled visit over time to Week 52</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of ranibizumab treatments during the study compared with annualized rate of intravitreal anti-VEGF treatments prior to baseline</measure>
    <time_frame>Baseline up to approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in center point thickness (CPT) on spectral-domain optical coherence tomography (SD-OCT) at each scheduled visit over time to Week 52</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who do not require supplemental treatment with intravitreal ranibizumab 0.5 mg prior to protocol-specified refill-exchanges</measure>
    <time_frame>Week 16 to Week 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with and without subretinal (SRF) and/or intraretinal fluid (IRF) on SD-OCT at baseline and over study duration</measure>
    <time_frame>Baseline up to approximately Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with ocular serious adverse events (SAEs)</measure>
    <time_frame>Day 1 up to approximately Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with ocular adverse events of special interest (AESIs)</measure>
    <time_frame>Day 1 to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with adverse device effects (ADEs) in the course of the study</measure>
    <time_frame>Day 1 to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with ocular AESIs during the postoperative period</measure>
    <time_frame>Baseline up to 37 days of initial implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with ocular AESIs during the intermediate postoperative period</measure>
    <time_frame>38 to 93 days after implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with ocular AESIs during the follow-up period</measure>
    <time_frame>From 37 days after implantation up to approximately 26 months</time_frame>
    <description>The investigator will follow each adverse event until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, the patient is lost to follow-up, or the patient withdraws consent.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Port Delivery System with Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will have the implant (filled prior to implantation with approximately 20 uL of the 100-mg/mL formulation of ranibizumab [approximately 2-mg dose of ranibizumab]) surgically inserted in the study eye at the Day 1 visit following their enrollment visit. After the initial fill of the implant with ranibizumab, patients will receive implant refill-exchanges at fixed 24-week intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Port Delivery System with Ranibizumab</intervention_name>
    <description>The ranibizumab 100 mg/mL will be administered to participants via the PDS implant</description>
    <arm_group_label>Port Delivery System with Ranibizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Ranibizumab Injection</intervention_name>
    <description>Ranibizumab (intravitreal 0.5-mg injections of 10 mg/mL formulation) will be used in the study eye as supplemental treatment. If a study patient discontinues study treatment, he/she may start receiving intravitreal ranibizumab injections in the study eye, per investigator's discretion.</description>
    <arm_group_label>Port Delivery System with Ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Ocular Inclusion Criteria&#xD;
&#xD;
          -  Initial diagnosis of nAMD within 6 to 18 months prior to the signing of the ICF&#xD;
&#xD;
          -  Previous treatment with at least 3 anti-VEGF injections other than ranibizumab for&#xD;
             nAMD per standard of care in the 9 months prior to PDS implantation; the most recent&#xD;
             anti-VEGF injection must have occurred within 12 weeks of PDS implantation&#xD;
&#xD;
          -  The last 2 anti-VEGF injections for nAMD prior to PDS implantation must be with the&#xD;
             same eligible anti-VEGF agent, either bevacizumab or aflibercept&#xD;
&#xD;
          -  Availability of historical visual acuity data and SD-OCT imaging prior to the first&#xD;
             anti-VEGF treatment for nAMD until the time of study enrollment&#xD;
&#xD;
          -  Availability of comprehensive historical anti-VEGF injection data including anti-VEGF&#xD;
             agent administered and date of administration from the first anti-VEGF treatment for&#xD;
             nAMD until the time of study enrollment&#xD;
&#xD;
          -  Demonstrated response to prior anti-VEGF intravitreal treatment since diagnosis BCVA&#xD;
             of 34 letters (approximate 20/200 Snellen equivalent) or better, using ETDRS chart at&#xD;
             a starting distance of 4 meters (see the BCVA manual for additional details) at&#xD;
             screening and enrollment visits&#xD;
&#xD;
          -  All subtypes of nAMD lesions are permissible&#xD;
&#xD;
          -  nAMD lesions at the time of diagnosis must involve the macula (6 mm diameter centered&#xD;
             at the fovea)&#xD;
&#xD;
          -  Sufficiently clear ocular media and adequate pupillary dilation to allow for clinical&#xD;
             exam and analysis and grading by the central reading center of SD-OCT images&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Study Eye&#xD;
&#xD;
          -  Prior vitrectomy surgery, submacular surgery, or other surgical intervention for AMD&#xD;
&#xD;
          -  Prior pars plana vitrectomy surgery&#xD;
&#xD;
          -  Prior treatment with ranibizumab&#xD;
&#xD;
          -  Prior treatment with verteporfin for injection, external-beam radiation therapy, or&#xD;
             transpupillary thermotherapy&#xD;
&#xD;
          -  Previous treatment with corticosteroid intravitreal injection&#xD;
&#xD;
          -  Previous intraocular device implantation excluding intraocular lenses&#xD;
&#xD;
          -  Previous intraocular surgery (including cataract surgery) within 3 months of study&#xD;
             enrollment&#xD;
&#xD;
          -  Previous laser (any type) used for AMD treatment&#xD;
&#xD;
          -  History of vitreous hemorrhage&#xD;
&#xD;
          -  History of rhegmatogenous retinal detachment&#xD;
&#xD;
          -  History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery&#xD;
&#xD;
          -  History of corneal transplant&#xD;
&#xD;
          -  History of conjunctival surgery in the superotemporal quadrant&#xD;
&#xD;
          -  Prior participation in a clinical trial involving any intravitreal anti-VEGF agents&#xD;
&#xD;
          -  Subretinal hemorrhage that involves the center of the fovea&#xD;
&#xD;
          -  Subfoveal fibrosis or subfoveal atrophy Retinal pigment epithelial tear&#xD;
&#xD;
          -  Any concurrent intraocular condition (e.g., cataract, glaucoma, diabetic retinopathy,&#xD;
             or epiretinal membrane) that would either require surgical intervention during the&#xD;
             study to prevent or treat visual loss that might result from that condition or affect&#xD;
             interpretation of study results&#xD;
&#xD;
          -  Rhegmatogenous retinal tears or peripheral retinal breaks on depressed fundus exam&#xD;
             that are untreated, or treated within the 3 months prior to study enrollment&#xD;
&#xD;
          -  Aphakia or absence of the posterior capsule&#xD;
&#xD;
          -  Previous violation of the posterior capsule is also an exclusion criterion unless it&#xD;
             occurred as a result of yttrium-aluminum garnet (YAG) laser posterior capsulotomy in&#xD;
             association with prior, posterior chamber intraocular lens implantation&#xD;
&#xD;
          -  Spherical equivalent of the refractive error demonstrating more than 8 diopters of&#xD;
             myopia or evidence of pathologic myopia on depressed fundus examination&#xD;
&#xD;
          -  Preoperative refractive error that exceeds 8 diopters of myopia, for patients who have&#xD;
             undergone prior refractive or cataract surgery&#xD;
&#xD;
          -  Spherical equivalent of the refractive error demonstrating more than 5 diopters of&#xD;
             hyperopia&#xD;
&#xD;
          -  Preoperative refractive error that exceeds 5 diopters of hyperopia, for patients who&#xD;
             have undergone prior refractive or cataract surgery&#xD;
&#xD;
          -  Uncontrolled ocular hypertension or glaucoma&#xD;
&#xD;
          -  Scleral pathology in the superotemporal quadrant&#xD;
&#xD;
          -  Conjunctival pathologies in the superotemporal quadrant&#xD;
&#xD;
          -  History or presence of severe posterior blepharitis, recurrent chalazia or hordeolum,&#xD;
             severe dry eye syndrome, or severe allergic conjunctivitis&#xD;
&#xD;
          -  Ectropion, entropion or other impairment of the upper or lower eyelid impacting lid&#xD;
             functionality needed to protect the ocular surface from exposure&#xD;
&#xD;
          -  Trichiasis&#xD;
&#xD;
          -  Corneal neuropathy&#xD;
&#xD;
          -  Lagophthalmos or incomplete blink&#xD;
&#xD;
          -  Active or history of facial nerve palsy/paresis&#xD;
&#xD;
        Either Eye&#xD;
&#xD;
          -  Prior treatment with brolucizumab (at any time prior to screening visit)&#xD;
&#xD;
          -  Prior treatment with any anti-VEGF biosimilar agents (at any time prior to screening&#xD;
             visit)&#xD;
&#xD;
          -  Prior treatment with external-beam radiation therapy or brachytherapy&#xD;
&#xD;
          -  MNV due to causes such as ocular histoplasmosis, trauma, or pathologic myopia&#xD;
&#xD;
          -  MNV due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia&#xD;
             MNV masquerading lesions (e.g., cone dystrophy, adult vitelliform dystrophy, pattern&#xD;
             dystrophy)&#xD;
&#xD;
          -  Any active or history of uveitis (e.g., idiopathic, drug-associated or&#xD;
             autoimmune-associated)&#xD;
&#xD;
          -  Active or history of keratitis, scleritis, or endophthalmitis&#xD;
&#xD;
          -  Suspected or active ocular or periocular infectious conjunctivitis or endophthalmitis&#xD;
&#xD;
          -  Active or history of Sjogrens syndrome or keratoconjunctivitis sicca&#xD;
&#xD;
          -  Active or history of floppy eyelid syndrome&#xD;
&#xD;
          -  Active or history of chronic eye rubbing&#xD;
&#xD;
          -  Active thyroid eye disease&#xD;
&#xD;
        Concurrent Systemic Conditions:&#xD;
&#xD;
          -  Uncontrolled blood pressure&#xD;
&#xD;
          -  Active or history of autoimmune diseases&#xD;
&#xD;
          -  History of stroke within the last 3 months prior to informed consent&#xD;
&#xD;
          -  Uncontrolled atrial fibrillation within 3 months of informed consent&#xD;
&#xD;
          -  History of myocardial infarction within the last 3 months prior to informed consent&#xD;
&#xD;
          -  History of other disease, metabolic dysfunction, or clinical laboratory finding giving&#xD;
             reasonable suspicion of a disease or condition that contraindicates the use of&#xD;
             ranibizumab or placement of the implant and that might affect interpretation of the&#xD;
             results of the study or renders the patient at high risk of treatment complications,&#xD;
             in the opinion of the investigator&#xD;
&#xD;
          -  Current active systemic infection&#xD;
&#xD;
          -  Use of any systemic anti-VEGF agents&#xD;
&#xD;
          -  Chronic use of oral corticosteroids&#xD;
&#xD;
          -  Active cancer within 12 months of enrollment except&#xD;
&#xD;
          -  Previous participation in any non-ocular (systemic) disease studies of investigational&#xD;
             drugs within 1 month preceding the informed consent&#xD;
&#xD;
          -  Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination&#xD;
             half-lives of the enrollment visit&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genetech</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML43000 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S.)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barnet Dulaney Perkins Eye Center</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Retina and Vitreous Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Eye Specialists Medical group Inc.</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Med Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Retina Med Group</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Retina Consultants</name>
      <address>
        <city>Durango</city>
        <state>Colorado</state>
        <zip>81303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Retina Associates, PC</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Group of New England</name>
      <address>
        <city>Waterford</city>
        <state>Connecticut</state>
        <zip>06385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ft Lauderdale Eye Institute</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialty Institute</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates of Florida</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711-1141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Retina and Macula Associates, PC</name>
      <address>
        <city>Oak Forest</city>
        <state>Illinois</state>
        <zip>60452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfe Eye Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Care Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmer Eye Institute Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-0005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Group of Washington</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Consultants</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants PC</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreoretinal Surgery</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Vision Research Foundation</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Carolina Retinal Associate PA</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation; Cole Eye Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Retina Center</name>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <zip>29501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Retina Center, LLC</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Retina PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Retina Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Texas</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Eye Center</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wagner Macula &amp; Retina Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

